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OBJECTIVES The study analyzed factors, including treatment, affecting disease-related death in patients
with hypertrophic cardiomyopathy (HCM) presenting in childhood.
BACKGROUND Previous smaller studies suggest that mortality is higher in patients with HCM presenting in
childhood compared with presentation in adulthood, but these studies have all originated
from selected patient populations in tertiary referral centers, and reported no significant
protection by treatment.
METHODS Retrospective comparisons of mortality were done in total cohort of patients presenting to
three regional centers of pediatric cardiology. There were 66 patients (25 with Noonan’s
syndrome) with HCM presenting at age ,19 years; mean follow-up was 12.0 years.
RESULTS Among risk factors for death were congestive heart failure (p 5 0.008), large electrocardio-
gram voltages (Sokolow-Lyon index p 5 0.0003), and degree of septal (p 5 0.004) and left
ventricular (p 5 0.028) hypertrophy expressed as percent of 95th centile value. The only
treatment that significantly reduced the risk of death on multifactorial analysis of variance was
high-dose beta-adrenoceptor antagonist therapy (propranolol 5 to 23 mg/kg/day or equiva-
lent; p 5 0.0001). Nineteen out of 40 patients managed conventionally (no treatment, 0.8 to
4 mg/kg of propranolol, or verapamil) died, median survival 15.8 years, with no deaths among
26 patients on high-dose beta-blockers (p 5 0.0004); survival proportions at 10 years were
0.65 (95% confidence interval 0.49–0.80) and 1.0, respectively (p 5 0.0015). Survival time
analysis shows better survival in the high-dose beta-blocker group compared with the “no
specific therapy” group (p 5 0.0009) and with the conventional-dose beta-blocker group (p 5
0.002). Hazard ratio analysis suggests that high-dose beta-blocker therapy produces a 5–10-
fold reduction in the risk of disease-related death.
CONCLUSIONS High-dose beta-blocker therapy improves survival in childhood HCM. (J Am Coll Cardiol
1999;34:1813–22) © 1999 by the American College of Cardiology
Hypertrophic cardiomyopathy (HCM) presenting in child-
hood has higher mortality (annual rate 4.6% to 5.8%) (1–3)
than in adult life (1% to 4%) (4,5). It has, however, been
suggested that high mortality figures are due to referral bias
of severe cases to institutions with research interests in
HCM (6). Observational studies in adults have suggested
possible benefits from treatment with verapamil (4), amio-
darone (7), or high-dose propranolol (8–10), and symptom-
atic infants and children obtain considerable benefit from
standard and high-dose propranolol treatment (11,12). The
aim of this study was to compare the impact of different
treatment strategies on the survival of patients with HCM,
with and without Noonan’s syndrome, presenting in child-
hood to three regional centers with a geographical basis for
referral.
METHODS
Study patients. All patients with a diagnosis of HCM
made before 19 years of age, and attending the Departments
of Pediatric Cardiology at the University Hospital (Lund),
the Academic Hospital (Uppsala), and the John Radcliffe
Hospital (Oxford), over the last 30 years, were included in
the study. In surviving patients at least one year of follow-up
was required for inclusion. All three hospitals were regional
centers with a geographical basis for patient referrals, and
the senior clinicians in each department were the same
throughout the study period, giving a consistency in ap-
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proach to treatment. Original patient records and echocar-
diographic data were re-examined, taking great care to
exclude all patients where the HCM was secondary to
maternal gestational diabetes, mitochondrial disorders, my-
opathies or Friedreich’s ataxia, or secondary to medical
therapy. A total of 66 patients with true primary HCM were
identified. The diagnosis of Noonan’s syndrome was based
on short stature and typical dysmorphic features. Follow-up
duration was up to 32.4 years (mean 12 years), and
follow-up information was obtained on all patients that had
moved. No patients were lost to follow-up. Autopsy infor-
mation and histological confirmation of the diagnosis were
both available on all subjects that died, except one child with
Noonan’s syndrome and classical severe HCM on echocar-
diography.
The treatment regimes identified were: 1) No medical
treatment at all, or diuretic therapy only, the “No Specific
Therapy” (NST) group (n 5 20); 2) Beta-adrenoceptor
antagonist therapy, propranolol in 89%, 1 to 23 mg/kg/day
(n 5 41); 3) Calcium-channel blockers (mostly verapamil
2.2 to 8.5 mg/kg/day; n 5 6). Fifteen patients following
treatment regimes 2 and 3 had additional anti-arrhythmic
therapy (quinidine, amiodarone, sotalol or disopyramide).
Measurements. Original electrocardiogram (ECG) trac-
ings and M-mode echocardiographic tracings were remea-
sured using standardized criteria. Sokolow-Lyon index (S in
lead V1 1 R in lead V5 or lead V6, whichever is largest) (13)
and the sum totals of R1S voltages in limb leads were
calculated. To judge relative severity of cardiac hypertrophy,
two types of ratios were employed. First, the ratios of septal
and posterior left ventricular (LV) wall thickness were
divided by the diastolic LV cavity diameter (septum-to-
cavity ratio and LV wall-to-cavity ratio). Second, the
observed values of septal and posterior wall thickness were
expressed as percent of the respective predicted 95th centile
values for age. Data on normal wall thickness values related
to body surface area were used for comparison with infants
up to six months of age (14), whereas for older children the
95th centile prediction limits for age were calculated from
200 normal children age 0 to 18 years in Oxford. These
normal data corresponded to those published by Feigen-
baum (15) for selected weight categories and at 18 years
predicted values equal to the upper limit of normal for
adults. The 95th centile prediction limit was calculated by
the equation 0.625 1 (age in years 3 0.0269) for septal
thickness and by 0.565 1 (age in years 3 0.030) for
posterior LV wall thickness.
Statistics. Statistical analysis was carried out using com-
mercial software (Statgraphics Plus, PRISM and CIA).
Kaplan-Meier survival curves with log-rank t test, and
confidence limits for survival proportions and hazard ratios,
were all calculated. The Fisher exact test was used for
categorical data analysis. The Mann-Whitney U test for
unpaired data was used for intergroup comparisons of
variables. Risk factors for death were analyzed by multivar-
iate correlation analysis (Statgraphics Plus). Multifactor
analysis of variance (ANOVA) was used to test that the
effect of treatment was independent from chance influence
of risk factor distribution (Statgraphics Plus). Response
variables were death or survival, coded as integers, and
treatment modality was the first factor. Only up to three
factors could be analyzed at a time, because of degrees of
freedom available, and thus the only treatment to show a
significant effect was analyzed sequentially together with all
identified risk factors. A significance level of ,0.05 of the
interaction between treatment and another factor would be
evidence that the treatment effect was not independent.
RESULTS
The patient groups in the three centers were very similar,
with no significant difference in the age of diagnosis, clinical
characteristics, proportion of cases with Noonan’s syn-
drome, or length of follow-up (see Table 1). Accordingly,
the patients were combined and analyzed as a single cohort
in terms of analysis of mortality and risk factors, although
HCM associated with Noonan’s syndrome was also ana-
Abbreviations and Acronyms
CCF 5 congestive heart failure
CDbB 5 conventional-dose beta-adrenoceptor
antagonist
CI 5 confidence interval
ECG 5 electrocardiogram
HCM 5 hypertrophic cardiomyopathy
HDbB 5 high-dose beta-adrenoceptor antagonist
LV 5 left ventricle/left ventricular
NST 5 no specific therapy
SE 5 standard error
Table 1. Comparison of Clinical Characteristics in Childhood HCM Cases at Different Centers
Center
Age at Diagnosis
in Years
(Mean 6 SE)
Total Follow-up
in Years
(Mean 6 SE)
Noonan’s
Syndrome
CCF at
Presentation
Family History of
Sudden Death
Oxford (n 5 29) 6.6 6 1.3 10.8 6 1.4 10/29 7/29 4/29
Lund (n 5 25) 6.3 6 1.1 12.9 6 2.0 11/25 4/25 3/25
Uppsala (n 5 12) 6.0 6 1.6 10.6 6 2.1 4/12 2/12 0/12
CCF 5 congestive heart failure; SE 5 standard error.
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lyzed separately and compared with HCM not associated
with Noonan’s syndrome.
Mortality. There were 66 patients with 789 patient years
and 19 deaths: 10 deaths were sudden, 4 were due to severe
congestive heart failure (CCF) in infants, 3 to sequelae of
late CCF in older patients, and 2 were related to surgical
myectomy. However, there were suggestive differences be-
tween the annual mortality rates among the dominant
treatment regimes. The NST group had an annual mortality
of 6.6% (n 5 20), with 3.5% annual mortality in the totally
asymptomatic subjects (n 5 14). The beta-adrenoceptor
antagonist group (n 5 41) had an annual mortality of 2.1%,
and the calcium-channel blocker group (n 5 6) had the
highest annual mortality, 10.5%.
Effect of treatment on mortality. Correlation analysis to
identify treatment factors influencing survival in the com-
bined groups showed a significant positive correlation be-
tween propranolol dose and survival (p 5 0.002), whereas
calcium channel-blocker therapy showed no correlation
with either death or survival (p 5 0.26; 0.63). As the
calcium-channel blocker group was very small, no further
statistical comparisons were made with this group. Figure 1
illustrates the beta-adrenoceptor blocking dose in
propranolol-equivalents in survivors and nonsurvivors
treated with beta-blockers, and it is notable that all the
deaths had occurred with doses in the low range (mean dose
[standard error, SE] in nonsurvivors 5 2.0 [0.2] mg/kg/day
as compared with 7.8 [1.0] mg/kg/day in survivors; p 5
0.015 Mann-Whitney U test). As previously published
studies had found no protection from conventional doses of
propranolol, the beta-blocker group was subdivided into
conventional-dose therapy (CDbB, n 5 18 patients; 0.8 to
4 mg/kg/day), and high-dose therapy (HDbB, n 5 26; 5 to
23 mg/kg/day of propranolol, or equivalent doses of meto-
prolol or atenolol in 3/26). There was a highly significant
correlation between HDbB and survival (p 5 0.0002; no
deaths among 26 patients on this treatment). However,
CDbB showed no significant correlation with survival, and
this group had an annual mortality of 4.3%.
Multifactor analysis of variance (ANOVA) confirmed
that out of all treatment regimes only HDbB significantly
reduced disease-related death (p 5 0.0001). A significant
proportion (10/26) of the patients in the HDbB group had
additional therapy with disopyramide, and accordingly the
group was further divided in HDbB as monotherapy, and in
HDbB combined with disopyramide. In the CDbB group,
3/18 patients had additional anti-arrhythmic therapy (so-
talol or amiodarone). Table 2 shows the clinical character-
istics of all the cases combined, and of the various identified
treatment subgroups. Four patients had treatment years on
two regimes included in analysis as they were alive on the
second regime: one with 5 years in the NST group and 2.2
years on CDbB; one with 4.0 years on CDbB and 8.2 years
on HDbB and disopyramide; one with 16.0 years on CDbB
and 4.2 years on HDbB and disopyramide; one with 2.8
years HDbB followed by 8.7 years of CDbB. Apart from
less severe degree of cardiac hypertrophy in the largely
asymptomatic NST group and no patients with a family
history of sudden death in this group, the treatment groups
are similar in all potential risk factors, except that the
combined HDbB plus disopyramide group tended toward
more severe hypertrophy.
Kaplan-Meier survival-time analysis showed that the
survival proportion of patients in the monotherapy HDbB
group was better than that of the NST group (log-rank test
p 5 0.006), and of that of the monotherapy CDbB group
(p 5 0.03; Fig. 2A). There was no significant difference
between the monotherapy CDbB group and the NST
group (Fig. 2A). The group with combined disopyramide
and HDbB (n 5 10; patients indicated by diamonds in Fig.
2B) also had a significantly better survival on log-rank test
than did the NST group (p 5 0.02) and the monotherapy
CDbB group (p 5 0.03). Comparing the total CDbB
group including patients with anti-arrhythmic therapy with
the total HDbB group (with and without disopyramide),
their survival curves also show a highly significant difference
in survival (p 5 0.004); likewise, the difference in survival
between the total HDbB group and the NST group is
highly significant (p 5 0.0009); see Figure 2B.
To quantify the treatment effect of high-dose beta-
blockers, the hazard ratios for death in the major treatment
groups are compared with the hazard of death in the NST
group set as 1.0 (as the risk approximating to natural
history) in Table 3. Only the HDbB groups, with or
without disopyramide, show a significant reduction in the
hazard of death, with the hazard ratios suggesting a 5–10-
fold reduction in risk.
As there were no significant differences in the survival
proportions among the NST, CDbB, and calcium-channel
blocker groups, these three treatment groups were pooled as
“conventional management” for a Kaplan-Meier plot illus-
Figure 1. Box-and-whisker plot illustrating the beta-blocker dose
in propranolol equivalents among patients receiving beta-blockers,
comparing survivors with nonsurvivors. The box encloses the
middle 50% of data values (i.e., 25th to 75th centile) with the
median indicated by a horizontal line, and the whiskers extend to
minimum and maximum values.
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trating total survival from the time of diagnosis (Fig. 3). The
advantage of this plot was that it allowed for the inclusion of
all treatment years in patients changing between different
treatment regimes, and of those dying on their second
regime, thus giving a truer picture of median survival after
diagnosis and of the annual mortality. With “conventional
management” there were 19 deaths among 40 patients
(44%), annual mortality 4.0%, as against no deaths among
the 26 patients on HDbB therapy (p 5 0.0004 on the
Fisher exact test), and the difference in survival is highly
significant on the log-rank test (p 5 0.0015). The survival
proportion 10 years after the diagnosis was estimated at 0.65
(95% CI [confidence interval] 0.49 to 0.80) in the “conven-
tional management” group, and the median survival from
diagnosis was 15.8 years.
In the “conventional management” group, 10/19 deaths
were sudden. The median age at sudden death was 13.3
years, and 6/10 sudden deaths occurred in the age range 9.8
to 13.5 years. However, there were no deaths in HDbB
group (p 5 0.006; Fisher exact test). Multiple ANOVA
confirms that HDbB significantly reduces the risk of
sudden death (p 5 0.0018).
Risk factors. To ascertain that the treatment groups were
comparable in their risk factors, we analyzed the clinical
features correlating with death in our cohort of patients. As
Figure 2. Kaplan-Meier survival curves comparing the survival of the different treatment groups described in Table 2. Survival time
analysis with each patient survival time (in years) indicated with a symbol at the time of death or when censored alive. (A) NST group
(n 5 20, filled circles); the monotherapy CDbB group (n 5 15, open triangles); and the monotherapy HDbB group (n 5 16, filled
triangles). (B) Total CDbB group (n 5 18) is shown with circles around patients with additional anti-arrhythmic therapy (n 5 3); total
HDbB group (n 5 26) is shown with filled diamonds for patients with additional disopyramide therapy (n 5 10). The NST group is
shown for reference (filled circles). See Results for statistical comparisons using log-rank t test.
Table 3. Hazard Ratios for Death as Compared With the NST Group
Group
5-Year Survival 10-Year Survival
Survival Proportion
(6SE)
Hazard Ratio
(95% CI)
Survival Proportion
(6SE)
Hazard Ratio
(95% CI)
NST group (n 5 20) 0.60 6 0.12 1.0 0.50 6 0.13 1.0
CDbB (no anti-arrhythmic drugs;
n 5 15)
0.71 6 0.13 0.57 (0.18 to 1.81) 0.49 6 0.16 0.75 (0.27 to 2.10)
CDbB (all patients, n 5 18) 0.76 6 0.11 0.52 (0.16 to 1.71) 0.60 6 0.13 0.64 (0.22 to 1.84)
HDbB (no disopyramide;
n 5 16)
1.0 0.15 (0.03 to 0.68) 1.0 0.15 (0.4 to 0.62)
HDbB (with disopyramide,
n 5 10)
1.0 0.19 (0.04 to 0.87) 1.0 0.19 (0.05 to 0.81)
HDbB (all combined, n 5 26) 1.0 0.08 (0.02 to 0.36) 1.0 0.08 (0.02 to 0.34)
Survival proportions were calculated with the Kaplan-Meier method, and comparisons between the NST group and each of the treatment groups were carried out by the log-rank
(Mantel-Hanszel) test.
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HDbB therapy had a significantly protective effect, patients
receiving this therapy were removed from the entire group
for statistical analysis of the risk factors for disease-related
death. In the remaining patients (n 5 40) multivariate
correlation analysis showed that the presence of heart failure
was positively correlated with the occurrence of death (p 5
0.002). The presence of ECG evidence of hypertrophy in
the form of a large Sokolow-Lyon index (p 5 0.0003) and
large sum of RS-voltages in limb leads (p 5 0.0008) also
showed a highly significant correlation with death. Echo-
cardiographic indices of cardiac hypertrophy at diagnosis
also showed positive correlation with death, both for
septum-to-cavity ratio (p 5 0.021), diastolic LV wall-to-
cavity ratio (p 5 0.043) and absolute septal and LV wall
thickness normalized for age by being expressed as percent-
age of 95th centile value (see Methods; p 5 0.004 and p 5
0.028). Multiple ANOVA on the total cohort of 66 patients
shows no significant interaction between any of the identi-
fied risk factors at presentation and the treatment effect of
HDbB.
Influence of Noonan’s syndrome. To determine whether
the effect of HDbB was affected by the genetic mechanism
underlying the HCM, we analyzed separately the effect of
HDbB in the 25 patients with Noonan’s syndrome and
HCM, and in HCM not associated with Noonan’s syn-
drome. In these subgroups there were no deaths among
eight Noonan patients on HDbB, but 10/17 of the Noonan
HCM patients on other regimes died (p 5 0.008 on the
Fisher exact test). Survival time analysis with log-rank test
confirms that HDbB confers a better survival than “con-
ventional management” both in HCM associated with
Noonan’s syndrome (p 5 0.03; see Fig. 4A), and with
non-Noonan childhood HCM (p 5 0.02; see Fig. 4B).
Among patients not on HDbB, sudden unexpected
deaths occurred in 4/17 patients with Noonan’s syndrome
(annual rate 2.3%), and in 6/21 patients with familial or
sporadic HCM (annual rate 2.3%).
Surgical myectomy. Six patients proceeded to myectomy
for reduction of LV outflow tract obstruction, one from the
NST group, three from the conventional-dose beta-blocker
group, and two from the calcium-channel-blocker group.
There was one reoperation, two perioperative deaths, and
two late deaths (annual mortality after the first operation
11.4%). The two medium-term survivors have recurrence of
outflow-obstruction or angina; thus, there is no patient with
a satisfactory medium-term result.
Disopyramide. Any beneficial effect of disopyramide on
survival cannot be separated from that of HDbB as all 10
patients receiving disopyramide are also in the HDbB
group. The indications for disopyramide were ventricular
tachycardia, paroxysmal atrial fibrillation with Wolff-
Parkinson-White syndrome, and in children ventricular
ectopics (Lown grade 2–3) or dynamic outflow-obstruction
persisting despite adequate beta-adrenoceptor blockade.
These patients remain in sinus rhythm with satisfactory
arrhythmia control and with no deaths over 85 patient years
in this high-risk group.
Amiodarone. Five patients received amiodarone therapy at
some stage, in doses of 100 (4 patients) to 200 mg/day.
Three patients had amiodarone discontinued because of side
effects; and one discontinued amiodarone as she was symp-
tomatically worse. There was one death (sudden) in 14
patient years, and no patient did well over the long term.
Side effects of drugs. Amiodarone had the highest propor-
tion of serious side effects (pulmonary, hepatic and thyroid),
but verapamil was also associated with a notably high
proportion of patients developing heart failure and progress-
ing to a dilated end-stage (3/6). The high-dose beta-blocker
therapy was tolerated in all patients, although in older
asymptomatic patients the dose has to be increased slowly
over 6 to 12 months to avoid undue fatigue on exertion.
Three patients have changed totally or partly from propran-
olol to metoprolol or atenolol due to bronchospasm (1
patient) or nightmares (2 patients). Two patients have had
an episode of hypoglycemia (with no sequelae) after more
than 18 h fasting, and parents should be advised to avoid
prolonged periods without food.
Patient acceptability of high-dose beta-blocker. Patients
in the higher beta-blocker dose range had their doses
increased from a starting dose of 1.5 to 3 mg/kg/day of
propranolol to a minimum of 6 mg/kg/day. Further dose
increases were determined by therapeutic response, and
24-h Holter monitoring was used to indicate that a pro-
found beta-receptor blockade had been achieved (see Fig.
Figure 3. Kaplan-Meier survival time analysis of total survival after
diagnosis. Patients in the HDbB group (n 5 26; filled triangles)
are compared with all the other patients, “conventional manage-
ment” (n 5 40; filled squares), showing a significantly improved
survival in the patients on HDbB (log-rank p 5 0.0015).
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5). This usually requires serum concentrations of propran-
olol between 200 and 900 mg/liter. When changing from
plain to slow-release propranolol a dose increase may be
needed to compensate for less complete absorption, partic-
ularly in young children. Patients adapt well to profound
beta-blockade and are able to manage schooling with good
academic results and full-time employment. Patients with
asthma have tolerated treatment with high-dose metoprolol
well, as long as prophylactic inhalers are used regularly.
Three pregnancies have proceeded uneventfully, with a
mother on 7.5 mg/kg of metoprolol, producing two healthy
infants with birth weights on the 3rd centile, and a mother
on 3.8 mg/kg of atenolol, 8.2 mg/kg of propranolol and
10.7 mg/kg of disopyramide producing an infant on the
50th centile with no neonatal problems. Any changeover
from nonselective to selective beta-blockers needs to be
carried out gradually with repeated 24-h ECG monitoring,
as we have seen re-emergence of previously well-controlled
ventricular arrhythmias when attempting to change from
propranolol to atenolol, and in one case had to settle for
combined treatment of atenolol and a reduced dose of
propranolol. Maximum exercise capability was curtailed
somewhat in patients with only mild hypertrophy at the
start of treatment, but generally improved in patients with
severe hypertrophy at the start of high-dose therapy. Only
one (asymptomatic) patient elected to discontinue high-
dose therapy because of reduced exercise-tolerance.
DISCUSSION
Mortality in a cohort study. The relative rarity of HCM
means that there is no report in the literature of any
prospective, randomized study of the long-term outcome of
any medical therapy for HCM. The even greater rarity of
HCM presenting in childhood makes it necessary to use
retrospective data to achieve sufficient patient years for an
initial comparison of different medical therapies. The
strength of the current study is that it assesses the outcome
of a total cohort of patients arising from regional centers
with a geographical basis for referral, therefore avoiding
recruitment bias and avoiding an over-representation of
severe cases as might be seen in tertiary centers with a
research interest in HCM. It is therefore not surprising that
the total mortality observed in the conventionally managed
group (4.0%) is slightly lower than figures previously re-
ported from specialized supraregional centers in the United
Kingdom and the U.S. (annual mortalities of 4.6% to 5.9%)
(1–3). Even with the lower rate of mortality in this study,
the median survival with conventional management is only
15.8 years, and 10/19 deaths were sudden, with the majority
occurring in asymptomatic 9 to 13-year-olds.
Role of progressive hypertrophy in childhood HCM.
Hypertrophic cardiomyopathy is a genetically heteroge-
neous condition, and over 70 mutations, all encoding
contractile proteins, have now been described (16). It has
Figure 4. Comparison of treatment effects in HCM patients with or without Noonan’s syndrome. Kaplan-Meier analysis of total survival
from diagnosis. (A) Noonan patients with conventional management (n 5 17; filled squares) compared with Noonan patients from the
total HDbB group (n 5 8; filled triangles); log-rank p 5 0.03. (B) Non-Noonan HCM patients with conventional management (n 5
21; open squares) compared with non-Noonan HCM patients from the total HDbB group (n 5 18; open triangles); log-rank p 5 0.02.
Two patients in the conventional management group with some dysmorphic features suggesting Noonan’s syndrome but of average or
above average height, one survivor and one nonsurvivor, could not retrospectively be assigned as either Noonan or non-Noonan and were
omitted.
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been suggested that the cardiac hypertrophy seen in HCM
is a compensatory phenomenon rather than being directly
caused by the mutations (16). Most adults presenting with
HCM were asymptomatic as children, but cardiac hyper-
trophy due to HCM can be rapidly progressive in child-
hood, particularly during adolescence (17). Previous studies
have looked for risk factors for sudden death only, and in
HCM patients of all ages failed to demonstrate a significant
correlation with absolute wall thickness (18). The present
study includes all disease-related deaths, and demonstrates
that in our cohort of HCM patients presenting in childhood
the risk of all disease-related death, and of sudden death,
increases with increasing cardiac hypertrophy when it is
expressed relative either to patient age or to cavity size. The
inference is therefore that medical therapy aimed at reduc-
ing progression of cardiac hypertrophy might be of benefit.
Effect of treatment on mortality in childhood HCM.
The only medical therapy that significantly reduced the risk
of death on multivariate ANOVA was HDbB therapy. No
deaths occurred among 26 patients with 199 patient years of
observation on high-dose beta-blocker treatment, including
113 patient years on monotherapy with beta-blockers. On
survival time analysis, both the group with monotherapy
and the group with high-dose beta-blocker and disopyr-
amide had a highly significant survival advantage compared
with both the NST group, whose annual mortality was
6.6%, and the conventional-dose beta-blocker group, whose
annual mortality was 4.3%. This result occurred despite the
high-dose beta-blocker group being extremely well matched
in risk factors with the conventional-dose group, and having
a higher incidence of risk factors than the NST group. The
size of this treatment effect appears large, with hazard ratios
Figure 5. The 24-h ECG recordings from patients with HCM and varying degrees of beta-receptor blockade. (A) A 24-h ECG trace from
9-month-old infant with severe HCM before starting therapy. (B) Same infant on 5 mg/kg/day of propranolol; maximum heart rate is
lower, but still up to 140 beats/min, and there is considerable variability. (C) Same infant, after serial increases to a dose of 20 mg
propranolol/kg/day in order to abolish a dynamic outflow gradient, now shows good beta-blockade, with awake heart rates mostly between
90 and 110 beats/min. (D) A young adult, with HCM first diagnosed at age 13 years, now on 14 mg/kg of propranolol/day. Despite the
very flat heart rate response (between 60 to 70 beats/min) she has no problems coping with full-time employment.
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suggesting protection in the order of a 5 to 10-fold
reduction in mortality. The treatment effect appears inde-
pendent of the genetic mechanism underlying the HCM, as
it is present both in HCM without and with Noonan’s
syndrome (Fig. 4). Treatment with conventional doses of
beta-blocker, particularly in the lower range of 2 to 3
mg/kg/day, did not protect against the occurrence of sudden
death, in agreement with previous studies (18).
Potential mechanism of the effect of beta-adrenoceptor
antagonists. Normal myocardial cells show both age-
related growth and compensatory hypertrophy. Animal
experimental evidence suggests that increased cardiac sym-
pathetic nervous activity is the most important trigger of
compensatory cardiac hypertrophy (19). Furthermore, ani-
mal experimental work has shown that, although high-dose
beta-adrenoceptor blockade does not reduce age-related
cardiac growth (20), it greatly reduces compensatory cardiac
hypertrophy through a mechanism independent of effect on
cardiac workload (20). In vivo this effect is exerted largely
via beta1-adrenoceptors (21). Increased activity of sympa-
thetic nerves in the heart is present in patients with HCM
(22) and may well be a compensatory reflex response to the
small LV cavity (23) and to the impaired diastolic filling in
HCM (24). Propranolol treatment improves diastolic func-
tion in HCM (25,26), but only large doses (480 mg/day in
adults) return iso-volumic relaxation time to normal (26). In
the group studied here a significant reduction in cardiac
hypertrophy in the group on high-dose beta-blocker therapy
was observed (12). As the heart is growing rapidly in
childhood it may represent a favorable window of opportu-
nity for pharmacological intervention.
There are earlier studies on adults with HCM that also
report very low (0% to 0.6%) annual mortality rates with
high-dose propranolol treatment (9,10), but neither of these
studies had control groups. It is known that conventional
and medium-sized doses of propranolol do not abolish
ventricular tachycardia in HCM (27,28), but it has been
speculated that propranolol might prevent ventricular tachy-
cardia degenerating into ventricular fibrillation (28), similar
to its postulated protective effect in ischemic heart disease
(29), and in this respect propranolol is probably better than
beta1-selective drugs.
Disopyramide. A substantial proportion of the HDbB
group had additional anti-arrhythmic treatment with diso-
pyramide, a drug that has beneficial hemodynamic effects in
HCM (30,31) with actions that are additive to the effects of
propranolol (32). This combination may have contributed
to the favorable outcome in the HDbB group combined
with disopyramide, which had particularly severe hypertro-
phy, but is not the sole cause of it, as disopyramide alone
does not appear to reduce risk of death in HCM patients
with nonsustained ventricular tachycardia (7). Furthermore,
the survival of patients on monotherapy with high-dose
adrenoceptor antagonist is just as good. Ventricular ectopics
are rare before puberty (33), and particularly if they do not
suppress at high heart rates they carry a risk of sudden death
in patients with structurally abnormal hearts (34). Thus, it is
probably appropriate to have a lower threshold for active
treatment of ventricular ectopy in childhood HCM than in
adults.
Current treatment practice. Since our analysis of the
mortality results from the first two centers in 1997 (12), our
threshold for active treatment is lower and, in addition to
symptomatic patients and patients with dynamic outflow
gradients or arrhythmias, all patients with a close family
history of sudden death or with severe or rapidly progressing
cardiac hypertrophy are recommended high-dose beta-
blocker therapy. Propranolol remains the first line drug (6 to
23 mg/kg), except where there is a history of bronchospasm
or hypoglycemia when we use metoprolol (6 to 12 mg/kg).
We use atenolol (3.6 to 8 mg/kg) only in patients with sleep
disturbance. High-dose beta-adrenoceptor blockade is asso-
ciated with reduction in cardiac hypertrophy (12), which has
been observed with propranolol, metoprolol and atenolol.
Uniformly high levels of beta-blocking drugs throughout
the 24 h are essential to maintain adequate heart rate control
at all times, and where possible we use slow-release pro-
pranolol (the granules from an opened capsule can be fed to
an infant, mixed in soft foods). We give plain propranolol
three times daily and slow-release propranolol, atenolol and
metoprolol twice daily.
Conclusions. Strong indications from this cohort study
support the medical management of HCM presenting in
childhood with HDbB therapy. This approach appears to
confer a significant survival advantage, with no mortality in
26 patients treated for 199 patient years, and a 5 to 10-fold
reduction in the hazard of death compared with the other
treatments studied. These observations make a strong case
for high-dose beta-blockers as the first-line treatment in
symptomatic childhood HCM, and for a prospective ran-
domized study of the use of high-dose beta-blocker therapy
in the asymptomatic prepubertal child with HCM.
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